Could the world be dealing with COVID-19 in all its mutations for decades to come?

Credit: Getty Images
Credit: Getty Images

We are currently faced with the question of how the CoV-2 severity may change in the years ahead. Our analysis of immunological and epidemiological data on endemic human coronaviruses (HCoVs) shows that infection-blocking immunity wanes rapidly, but disease-reducing immunity is long-lived.

Our model, incorporating these components of immunity, recapitulates both the current severity of CoV-2 and the benign nature of HCoVs, suggesting that once the endemic phase is reached and primary exposure is in childhood, CoV-2 may be no more virulent than the common cold.

We predict a different outcome for an emergent coronavirus that causes severe disease in children. These results reinforce the importance of behavioral containment during pandemic vaccine rollout, while prompting us to evaluate scenarios for continuing vaccination in the endemic phase.

If frequent boosting of immunity by ongoing virus circulation is required to maintain protection from pathology, then it may be best for the vaccine to mimic natural immunity insofar as preventing pathology without blocking ongoing virus circulation.

Related article:  ‘Cutting-edge’ artificial cells could boost precision medicine efforts

Preliminary results suggest the adenovirus-based vaccine is better at preventing severe than mild or asymptomatic infections, and it will be important to collect similar data for the other vaccines.

Should the vaccine cause a major reduction in transmission, it might be important to consider strategies that target delivery to older individuals for whom infection can cause higher morbidity and mortality, while allowing natural immunity and transmission to be maintained in younger individuals.

Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

The findings presented here suggest that using symptoms as a surveillance tool to curb the virus’s spread will become more difficult, as milder reinfections increasingly contribute to chains of transmission and population level attack rates.

In addition, infection or vaccination may protect against disease but not provide the type of transmission-blocking immunity that allows for shielding or the generation of long-term herd immunity.

Read the original post

Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: What are mRNA COVID-19 vaccines and how do they work?

Infographic: What are mRNA COVID-19 vaccines and how do they work?

As of 1 December 2020, thirteen vaccines have reached the final stage of testing: where they are being given to ...

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend